Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

Alzheimer's and Dementia

Volumn 12, Issue 10, 2016, Pages 1051-1065

  Khanna, Mansi R ^a   Kovalevich, Jane ^a   Lee, Virginia M Y ^a   Trojanowski, John Q ^a   Brunden, Kurt R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Amyloid; Drugs; Fibrils; Microtubules; Neurons; Tau; Tauopathy; Therapeutics

Indexed keywords

NOOTROPIC AGENT; TAU PROTEIN;

HUMAN; IMMUNOTHERAPY; MICROTUBULE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; TAUOPATHY; ALZHEIMER DISEASE; BRAIN; FRONTOTEMPORAL LOBAR DEGENERATION; METABOLISM; PATHOLOGY; TAUOPATHIES;

ALZHEIMER DISEASE; BRAIN; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; TAU PROTEINS; TAUOPATHIES;

EID: 84995451096     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.06.006     Document Type: Review

References (211)

1. [1] Kidd, M., Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197 (1963), 192–193.
2. [2] Lee, V.M.Y., Balin, B.J., Otvos, L., Trojanowski, J.Q., A68: a major subunit of paired helical filaments and derivatized forms of normal-Tau. Science 251 (1991), 675–678.
3. [3] Irwin, D.J., Cairns, N.J., Grossman, M., McMillan, C.T., Lee, E.B., Van Deerlin, V.M., et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol 129 (2015), 469–491.
4. [4] Gardner, A., Iverson, G.L., McCrory, P., Chronic traumatic encephalopathy in sport: a systematic review. Br J Sports Med 48 (2014), 84–90.
5. [5] Hazrati, L.N., Tartaglia, M.C., Diamandis, P., Davis, K.D., Green, R.E., Wennberg, R., et al. Absence of chronic traumatic encephalopathy in retired football players with multiple concussions and neurological symptomatology. Front Hum Neurosci, 7, 2013, 222.
6. [6] McKee, A.C., Cairns, N.J., Dickson, D.W., Folkerth, R.D., Dirk Keene, C., Litvan, I., et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 131 (2016), 75–86.
7. [7] McKee, A.C., Stein, T.D., Kiernan, P.T., Alvarez, V.E., The neuropathology of chronic traumatic encephalopathy. Brain Pathol 25 (2015), 350–364.
8. [8] Lee, V.M.Y., Goedert, M., Trojanowski, J.Q., Neurodegenerative tauopathies. Annu Rev Neurosci 24 (2001), 1121–1159.
9. [9] Crary, J.F., Trojanowski, J.Q., Schneider, J.A., Abisambra, J.F., Abner, E.L., Alafuzoff, I., et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128 (2014), 755–766.
10. [10] Jellinger, K.A., Alafuzoff, I., Attems, J., Beach, T.G., Cairns, N.J., Crary, J.F., et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol 129 (2015), 757–762.
11. [11] Boxer, A.L., Lang, A.E., Grossman, M., Knopman, D.S., Miller, B.L., Schneider, L.S., et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 13 (2014), 676–685.
12. [12] Drechsel, D.N., Hyman, A.A., Cobb, M.H., Kirschner, M.W., Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3 (1992), 1141–1154.
13. [13] Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.M., Mandelkow, E., Domains of tau-protein and interactions with microtubules. Biochemistry 33 (1994), 9511–9522.
14. [14] Stamer, K., Vogel, R., Thies, E., Mandelkow, E., Mandelkow, E.M., Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156 (2002), 1051–1063.
15. [15] Vershinin, M., Carter, B.C., Razafsky, D.S., King, S.J., Gross, S.P., Multiple-motor based transport and its regulation by Tau. Proc Natl Acad Sci U S A 104 (2007), 87–92.
16. [16] Dixit, R., Ross, J.L., Goldman, Y.E., Holzbaur, E.L.F., Differential regulation of dynein and kinesin motor proteins by tau. Science 319 (2008), 1086–1089.
17. [17] Bramblett, G.T., Trojanowski, J.Q., Lee, V.M.Y., Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent-tau and accumulation of abnormal tau-isoforms (A68 Proteins). Lab Invest 66 (1992), 212–222.
18. [18] Alonso, A.D., GrundkeIqbal, I., Iqbal, K., Abnormally phosphorylated-tau from Alzheimer-disease brain depolymerizes microtubules. Neurobiol Aging, 15, 1994, S37.
19. [19] Wagner, U., Utton, M., Gallo, J.M., Miller, C.C.J., Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 109 (1996), 1537–1543.
20. [20] Merrick, S.E., Trojanowski, J.Q., Lee, V.M.Y., Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons (NT2N cells). J Neurosci 17 (1997), 5726–5737.
21. [21] Ballatore, C., Lee, V.M.Y., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8 (2007), 663–672.
22. [22] Wilcock, G.K., Esiri, M.M., Plaques, tangles and dementia—a quantitative study. J Neurol Sci 56 (1982), 343–356.
23. [23] Arriagada, P.V., Growdon, J.H., Hedleywhyte, E.T., Hyman, B.T., Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992), 631–639.
24. [24] Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41 (1997), 17–24.
25. [25] Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B.I., et al. Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17. Science 282 (1998), 1914–1917.
26. [26] Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998), 702–705.
27. [27] Brunden, K.R., Trojanowski, J.Q., Lee, V.M.Y., Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8 (2009), 783–793.
28. [28] Kovacs, G.G., Ferrer, I., Grinberg, L.T., Alafuzoff, I., Attems, J., Budka, H., et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131 (2016), 87–102.
29. [29] Min, S.W., Cho, S.H., Zhou, Y.G., Schroeder, S., Haroutunian, V., Seeley, W.W., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67 (2010), 953–966.
30. [30] Cohen, T.J., Guo, J.L., Hurtado, D.E., Kwong, L.K., Mills, I.P., Trojanowski, J.Q., et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun, 2, 2011, 252.
31. [31] Lefebvre, T., Ferreira, S., Dupont-Wallois, L., Bussiere, T., Dupire, M.J., Delacourte, A., et al. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins—a role in nuclear localization. Biochim Biophys Acta 1619 (2003), 167–176.
32. [32] Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G.W., Gong, C.X., O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101 (2004), 10804–10809.
33. [33] Gong, C.X., Liu, F., Grundke-Iqbal, I., Iqbal, K., Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 112 (2005), 813–838.
34. [34] Morris, M., Knudsen, G.M., Maeda, S., Trinidad, J.C., Ioanoviciu, A., Burlingame, A.L., et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18 (2015), 1183–1189.
35. [35] Marcus, J.N., Schachter, J., Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease. J Neurogenet 25 (2011), 127–133.
36. [36] Ksiezak-Reding, H., Liu, W.K., Yen, S.H., Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res 597 (1992), 209–219.
37. [37] Kopke, E., Tung, Y.C., Shaikh, S., Alonso, A.D., Iqbal, K., GrundkeIqbal, I., Microtubule-associated protein-tau—abnormal phosphorylation of a non-paired helical filament pool in Alzheimer-disease. J Biol Chem 268 (1993), 24374–24384.
38. [38] Matsuo, E.S., Shin, R.W., Billingsley, M.L., Vandevoorde, A., Oconnor, M., Trojanowski, J.Q., et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's-disease paired helical filament-tau. Neuron 13 (1994), 989–1002.
39. [39] Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., et al. Proline-directed and non-proline-directed phosphorylation of Phf-tau. J Biol Chem 270 (1995), 823–829.
40. [40] Hasegawa, M., Morishimakawashima, M., Takio, K., Suzuki, M., Titani, K., Ihara, Y., Protein-sequence and mass-spectrometric analyses of tau in the Alzheimer's-disease brain. J Biol Chem 267 (1992), 17047–17054.
41. [41] Hanger, D.P., Betts, J.C., Loviny, T.L.F., Blackstock, W.P., Anderton, B.H., New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71 (1998), 2465–2476.
42. [42] Lee, V.M.Y., Daughenbaugh, R., Trojanowski, J.Q., Microtubule stabilizing drugs for the treatment of Alzheimer's-disease. Neurobiol Aging 15 (1994), S87–S89.
43. [43] Brunden, K.R., Yao, Y., Potuzak, J.S., Ferrar, N.I., Ballatore, C., James, M.J., et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res 63 (2011), 341–351.
44. [44] Brunden, K.R., Trojanowski, J.Q., Smith, A.B. 3rd, Lee, V.M., Ballatore, C., Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorg Med Chem 22 (2014), 5040–5049.
45. [45] Alonso, A.D., GrundkeIqbal, I., Iqbal, K., Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2 (1996), 783–787.
46. [46] Necula, M., Kuret, J., Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem 279 (2004), 49694–49703.
47. [47] Mazanetz, M.P., Fischer, P.M., Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6 (2007), 464–479.
48. [48] Gong, C.X., Iqbal, K., Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15 (2008), 2321–2328.
49. [49] Hanger, D.P., Anderton, B.H., Noble, W., Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15 (2009), 112–119.
50. [50] Tell, V., Hilgeroth, A., Recent developments of protein kinase inhibitors as potential AD therapeutics. Front Cell Neurosci, 7, 2013, 189.
51. [51] Martin, L., Latypova, X., Wilson, C.M., Magnaudeix, A., Perrin, M.L., Yardin, C., et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev 12 (2013), 289–309.
52. [52] Yamaguchi, H., Ishiguro, K., Uchida, T., Takashima, A., Lemere, C.A., Imahori, K., Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK)I glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92 (1996), 232–241.
53. [53] Imahori, K., Uchida, T., Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem 121 (1997), 179–188.
54. [54] Pei, J.J., Grundke-Iqbal, I., Iqbal, K., Bogdanovic, N., Winblad, B., Cowburn, R.F., Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 797 (1998), 267–277.
55. [55] Augustinack, J.C., Sanders, J.L., Tsai, L.H., Hyman, B.T., Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J Neuropathol Exp Neurol 61 (2002), 557–564.
56. [56] Spittaels, K., Van Den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., et al. Glycogen synthase kinase-3 beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275 (2000), 41340–41349.
57. [57] Lucas, J.J., Hernandez, F., Gomez-Ramos, P., Moran, M.A., Hen, R., Avila, J., Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3 beta conditional transgenic mice. EMBO J 20 (2001), 27–39.
58. [58] Hernandez, F., Borrell, J., Guaza, C., Avila, J., Lucas, J.J., Spatial learning deficit in transgenic mice that conditionally over-express GSK-3 beta in the brain but do not form tau filaments. J Neurochem 83 (2002), 1529–1533.
59. [59] Ahlijanian, M.K., Barrezueta, N.X., Williams, R.D., Jakowski, A., Kowsz, K.P., McCarthy, S., et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 97 (2000), 2910–2915.
60. [60] Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38 (2003), 555–565.
61. [61] Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102 (2005), 6990–6995.
62. [62] Perez, M., Hernandez, F., Lim, F., Diaz-Nido, J., Avila, J., Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5 (2003), 301–308.
63. [63] Nakashima, H., Ishihara, T., Suguimoto, P., Yokota, O., Oshima, E., Kugo, A., et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 110 (2005), 547–556.
64. [64] Le Corre, S., Klafki, H.W., Plesnila, N., Hubinger, G., Obermeier, A., Sahagun, H., et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 103 (2006), 9673–9678.
65. [65] Hampel, H., Ewers, M., Burger, K., Annas, P., Mortberg, A., Bogstedt, A., et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70 (2009), 922–931.
66. [66] Tolosa, E., Litvan, I., Hoglinger, G.U., Burn, D., Lees, A., Andres, M.V., et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29 (2014), 470–478.
67. [67] Lovestone, S., Boada, M., Dubois, B., Hull, M., Rinne, J.O., Huppertz, H.J., et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis 45 (2015), 75–88.
68. [68] Rayasam, G.V., Tulasi, V.K., Sodhi, R., Davis, J.A., Ray, A., Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156 (2009), 885–898.
69. [69] Robertson, L.A., Moya, K.L., Breen, K.C., The potential role of tau protein O-glycosylation in Alzheimer's disease. J Alzheimers Dis 6 (2004), 489–495.
70. [70] Yuzwa, S.A., Cheung, A.H., Okon, M., McIntosh, L.P., Vocadlo, D.J., O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J Mol Biol 426 (2014), 1736–1752.
71. [71] Yuzwa, S.A., Shan, X., Macauley, M.S., Clark, T., Skorobogatko, Y., Vosseller, K., et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol 8 (2012), 393–399.
72. [72] Yuzwa, S.A., Macauley, M.S., Heinonen, J.E., Shan, X.Y., Dennis, R.J., He, Y.A., et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4 (2008), 483–490.
73. [73] Graham, D.L., Gray, A.J., Joyce, J.A., Yu, D., O'Moore, J., Carlson, G.A., et al. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology 79 (2014), 307–313.
74. [74] Borghgraef, P., Menuet, C., Theunis, C., Louis, J.V., Devijver, H., Maurin, H., et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of tau.P301L mice. PLoS One, 8, 2013, e84442.
75. [75] Min, S.W., Chen, X., Tracy, T.E., Li, Y.Q., Zhou, Y.G., Wang, C., et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21 (2015), 1154–1162.
76. [76] Rissman, R.A., Poon, W.W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M.P., et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114 (2004), 121–130.
77. [77] Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100 (2003), 10032–10037.
78. [78] Guillozet-Bongaarts, A.L., Garcia-Sierra, F., Reynolds, M.R., Horowitz, P.M., Fu, Y., Wang, T., et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 26 (2005), 1015–1022.
79. [79] Newman, J., Rissman, R.A., Sarsoza, F., Kim, R.C., Dick, M., Bennett, D.A., et al. Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol 110 (2005), 135–144.
80. [80] Zhao, Y., Tseng, I.C., Heyser, C.J., Rockenstein, E., Mante, M., Adame, A., et al. Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron 87 (2015), 963–975.
81. [81] Zhang, Q., Zhang, X., Sun, A., Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models. Acta Neuropathol 117 (2009), 687–697.
82. [82] de Calignon, A., Fox, L.M., Pitstick, R., Carlson, G.A., Bacskai, B.J., Spires-Jones, T.L., et al. Caspase activation precedes and leads to tangles. Nature 464 (2010), 1201–1204.
83. [83] Guo, H., Albrecht, S., Bourdeau, M., Petzke, T., Bergeron, C., LeBlanc, A.C., Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 165 (2004), 523–531.
84. [84] Horowitz, P.M., Patterson, K.R., Guillozet-Bongaarts, A.L., Reynolds, M.R., Carroll, C.A., Weintraub, S.T., et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci 24 (2004), 7895–7902.
85. [85] Wang, Y., Garg, S., Mandelkow, E.M., Mandelkow, E., Proteolytic processing of tau. Biochem Soc Trans 38 (2010), 955–961.
86. [86] Albrecht, S., Bourdeau, M., Bennett, D., Mufson, E.J., Bhattacharjee, M., LeBlanc, A.C., Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol 170 (2007), 1200–1209.
87. [87] Ramcharitar, J., Albrecht, S., Afonso, V.M., Kaushal, V., Bennett, D.A., Leblanc, A.C., Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease. J Neuropathol Exp Neurol 72 (2013), 824–832.
88. [88] Basurto-Islas, G., Luna-Munoz, J., Guillozet-Bongaarts, A.L., Binder, L.I., Mena, R., Garcia-Sierra, F., Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol 67 (2008), 470–483.
89. [89] Park, S.Y., Ferreira, A., The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci 25 (2005), 5365–5375.
90. [90] Ferreira, A., Bigio, E.H., Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med 17 (2011), 676–685.
91. [91] Garg, S., Timm, T., Mandelkow, E.M., Mandelkow, E., Wang, Y., Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol Aging 32 (2011), 1–14.
92. [92] Reinecke, J.B., DeVos, S.L., McGrath, J.P., Shepard, A.M., Goncharoff, D.K., Tait, D.N., et al. Implicating calpain in tau-mediated toxicity in vivo. PLoS One, 6, 2011, e23865.
93. [93] Zhang, Z., Song, M., Liu, X., Kang, S.S., Kwon, I.S., Duong, D.M., et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat Med 20 (2014), 1254–1262.
94. [94] Rao, M.V., McBrayer, M.K., Campbell, J., Kumar, A., Hashim, A., Sershen, H., et al. Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci 34 (2014), 9222–9234.
95. [95] Olesen, O.F., Proteolytic degradation of microtubule associated protein tau by thrombin. Biochem Biophys Res Commun 201 (1994), 716–721.
96. [96] Wang, X., An, S., Wu, J.M., Specific processing of native and phosphorylated tau protein by proteases. Biochem Biophys Res Commun 219 (1996), 591–597.
97. [97] Arai, T., Guo, J.P., McGeer, P.L., Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem 280 (2005), 5145–5153.
98. [98] Bednarski, E., Lynch, G., Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L. J Neurochem 67 (1996), 1846–1855.
99. [99] Kenessey, A., Nacharaju, P., Ko, L.W., Yen, S.H., Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J Neurochem 69 (1997), 2026–2038.
100. [100] Malik, M., Fenko, M.D., Sheikh, A.M., Wen, G., Li, X., A novel approach for characterization of cathepsin D protease and its effect on tau and beta-amyloid proteins. Neurochem Res 36 (2011), 754–760.
101. [101] Arai, T., Miklossy, J., Klegeris, A., Guo, J.P., McGeer, P.L., Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 65 (2006), 19–25.
102. [102] Khlistunova, I., Biernat, J., Wang, Y., Pickhardt, M., von Bergen, M., Gazova, Z., et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281 (2006), 1205–1214.
103. [103] Wang, Y., Martinez-Vicente, M., Kruger, U., Kaushik, S., Wong, E., Mandelkow, E.M., et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 18 (2009), 4153–4170.
104. [104] Banay-Schwartz, M., DeGuzman, T., Kenessey, A., Palkovits, M., Lajtha, A., The distribution of cathepsin D activity in adult and aging human brain regions. J Neurochem 58 (1992), 2207–2211.
105. [105] Kenessey, A., Banay-Schwartz, M., DeGuzman, T., Lajtha, A., Increase in cathepsin D activity in rat brain in aging. J Neurosci Res 23 (1989), 454–456.
106. [106] Fernandez-Montoya, J., Perez, M., Cathepsin D in a murine model of frontotemporal dementia with Parkinsonism-linked to chromosome 17. J Alzheimers Dis 45 (2015), 1–14.
107. [107] Bi, X., Haque, T.S., Zhou, J., Skillman, A.G., Lin, B., Lee, C.E., et al. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus. J Neurochem 74 (2000), 1469–1477.
108. [108] Kuret, J., Congdon, E.E., Li, G., Yin, H., Yu, X., Zhong, Q., Evaluating triggers and enhancers of tau fibrillization. Microsc Res Tech 67 (2005), 141–155.
109. [109] Morris, A.M., Watzky, M.A., Agar, J.N., Finke, R.G., Fitting neurological protein aggregation kinetic data via a 2-step, minimal/“Ockham's razor” model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth. Biochemistry 47 (2008), 2413–2427.
110. [110] Naiki, H., Higuchi, K., Hosokawa, M., Takeda, T., Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 177 (1989), 244–249.
111. [111] Biancalana, M., Koide, S., Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 1804 (2010), 1405–1412.
112. [112] Goedert, M., Jakes, R., Spillantini, M.G., Hasegawa, M., Smith, M.J., Crowther, R.A., Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383 (1996), 550–553.
113. [113] Hasegawa, M., Crowther, R.A., Jakes, R., Goedert, M., Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J Biol Chem 272 (1997), 33118–33124.
114. [114] Wischik, C.M., Edwards, P.C., Lai, R.Y., Roth, M., Harrington, C.R., Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93 (1996), 11213–11218.
115. [115] Necula, M., Chirita, C.N., Kuret, J., Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44 (2005), 10227–10237.
116. [116] Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280 (2005), 7614–7623.
117. [117] Crowe, A., Huang, W., Ballatore, C., Johnson, R.L., Hogan, A.M., Huang, R., et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48 (2009), 7732–7745.
118. [118] Crowe, A., James, M.J., Lee, V.M., Smith, A.B., Trojanowski, J.Q., Ballatore, C., et al. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem 288 (2013), 11024–11037.
119. [119] Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E.M., Mandelkow, E., et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 46 (2007), 9215–9219.
120. [120] Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 280 (2005), 3628–3635.
121. [121] Brunden, K.R., Ballatore, C., Crowe, A., Smith, A.B., Lee, V.M., Trojanowski, J.Q., Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223 (2010), 304–310.
122. [122] Akoury, E., Pickhardt, M., Gajda, M., Biernat, J., Mandelkow, E., Zweckstetter, M., Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew Chem Int Ed Engl 52 (2013), 3511–3515.
123. [123] Congdon, E.E., Wu, J.W., Myeku, N., Figueroa, Y.H., Herman, M., Marinec, P.S., et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8 (2012), 609–622.
124. [124] Hochgrafe, K., Sydow, A., Matenia, D., Cadinu, D., Konen, S., Petrova, O., et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun, 3, 2015, 25.
125. [125] Wischik, C.M., Staff, R.T., Wischik, D.J., Bentham, P., Murray, A.D., Storey, J.M., et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 44 (2015), 705–720.
126. [126] Wischik, C.M., Harrington, C.R., Storey, J.M., Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 88 (2014), 529–539.
127. [127] Chirita, C., Necula, M., Kuret, J., Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43 (2004), 2879–2887.
128. [128] Congdon, E.E., Necula, M., Blackstone, R.D., Kuret, J., Potency of a tau fibrillization inhibitor is influenced by its aggregation state. Arch Biochem Biophys 465 (2007), 127–135.
129. [129] Crowe, A., Ballatore, C., Hyde, E., Trojanowski, J.Q., Lee, V.M., High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 358 (2007), 1–6.
130. [130] Arkin, M.R., Wells, J.A., Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3 (2004), 301–317.
131. [131] Dou, F., Netzer, W.J., Tanemura, K., Li, F., Hartl, F.U., Takashima, A., et al. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A 100 (2003), 721–726.
132. [132] Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A 104 (2007), 9511–9516.
133. [133] Tortosa, E., Santa-Maria, I., Moreno, F., Lim, F., Perez, M., Avila, J., Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis 17 (2009), 319–325.
134. [134] Karagoz, G.E., Duarte, A.M., Akoury, E., Ippel, H., Biernat, J., Moran Luengo, T., et al. Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell 156 (2014), 963–974.
135. [135] Dickey, C.A., Dunmore, J., Lu, B., Wang, J.W., Lee, W.C., Kamal, A., et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20 (2006), 753–755.
136. [136] Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., Grover, A., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13 (2004), 703–714.
137. [137] Jinwal, U.K., Akoury, E., Abisambra, J.F., O'Leary, J.C. 3rd, Thompson, A.D., Blair, L.J., et al. Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J 27 (2013), 1450–1459.
138. [138] Saidi, L.J., Polydoro, M., Kay, K.R., Sanchez, L., Mandelkow, E.M., Hyman, B.T., et al. Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes. J Alzheimers Dis 44 (2015), 937–947.
139. [139] Dickey, C.A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R.M., Dunmore, J., et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117 (2007), 648–658.
140. [140] Shimura, H., Schwartz, D., Gygi, S.P., Kosik, K.S., CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279 (2004), 4869–4876.
141. [141] Hatakeyama, S., Matsumoto, M., Kamura, T., Murayama, M., Chui, D.H., Planel, E., et al. U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. J Neurochem 91 (2004), 299–307.
142. [142] Dickey, C.A., Yue, M., Lin, W.L., Dickson, D.W., Dunmore, J.H., Lee, W.C., et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci 26 (2006), 6985–6996.
143. [143] Sahara, N., Murayama, M., Mizoroki, T., Urushitani, M., Imai, Y., Takahashi, R., et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 94 (2005), 1254–1263.
144. [144] Fontaine, S.N., Martin, M.D., Akoury, E., Assimon, V.A., Borysov, S., Nordhues, B.A., et al. The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Hum Mol Genet 24 (2015), 3971–3981.
145. [145] Fontaine, S.N., Rauch, J.N., Nordhues, B.A., Assimon, V.A., Stothert, A.R., Jinwal, U.K., et al. Isoform-selective genetic inhibition of constitutive cytosolic Hsp70 activity promotes client tau degradation using an altered co-chaperone complement. J Biol Chem 290 (2015), 13115–13127.
146. [146] Keller, J.N., Gee, J., Ding, Q., The proteasome in brain aging. Ageing Res Rev 1 (2002), 279–293.
147. [147] Keller, J.N., Hanni, K.B., Markesbery, W.R., Impaired proteasome function in Alzheimer's disease. J Neurochem 75 (2000), 436–439.
148. [148] Keck, S., Nitsch, R., Grune, T., Ullrich, O., Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 85 (2003), 115–122.
149. [149] Han, D.H., Na, H.K., Choi, W.H., Lee, J.H., Kim, Y.K., Won, C., et al. Direct cellular delivery of human proteasomes to delay tau aggregation. Nat Commun, 5, 2014, 5633.
150. [150] Bence, N.F., Sampat, R.M., Kopito, R.R., Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001), 1552–1555.
151. [151] Berger, Z., Ravikumar, B., Menzies, F.M., Oroz, L.G., Underwood, B.R., Pangalos, M.N., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15 (2006), 433–442.
152. [152] Majumder, S., Richardson, A., Strong, R., Oddo, S., Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One, 6, 2011, e25416.
153. [153] Schaeffer, V., Lavenir, I., Ozcelik, S., Tolnay, M., Winkler, D.T., Goedert, M., Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 135 (2012), 2169–2177.
154. [154] Rodriguez-Navarro, J.A., Rodriguez, L., Casarejos, M.J., Solano, R.M., Gomez, A., Perucho, J., et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis 39 (2010), 423–438.
155. [155] Kruger, U., Wang, Y., Kumar, S., Mandelkow, E.M., Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging 33 (2012), 2291–2305.
156. [156] Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One, 8, 2013, e62459.
157. [157] Shimada, K., Motoi, Y., Ishiguro, K., Kambe, T., Matsumoto, S.E., Itaya, M., et al. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol Dis 46 (2012), 101–108.
158. [158] Soga, S., Akinaga, S., Shiotsu, Y., Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 19 (2013), 366–376.
159. [159] Kamal, A., Boehm, M.F., Burrows, F.J., Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10 (2004), 283–290.
160. [160] Polak, P., Hall, M.N., mTOR and the control of whole body metabolism. Curr Opin Cell Biol 21 (2009), 209–218.
161. [161] Wolfe, D.M., Lee, J.H., Kumar, A., Lee, S., Orenstein, S.J., Nixon, R.A., Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci 37 (2013), 1949–1961.
162. [162] Boland, B., Kumar, A., Lee, S., Platt, F.M., Wegiel, J., Yu, W.H., et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci 28 (2008), 6926–6937.
163. [163] Dawson, H.N., Cantillana, V., Jansen, M., Wang, H., Vitek, M.P., Wilcock, D.M., et al. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 169 (2010), 516–531.
164. [164] Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., et al. Altered microtubule organization in small-caliber axons of mice lacking tau-protein. Nature 369 (1994), 488–491.
165. [165] Ikegami, S., Harada, A., Hirokawa, N., Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett 279 (2000), 129–132.
166. [166] Ma, Q.L., Zuo, X., Yang, F., Ubeda, O.J., Gant, D.J., Alaverdyan, M., et al. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci 34 (2014), 7124–7136.
167. [167] Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F.R., Cheng, I.H., Wu, T., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007), 750–754.
168. [168] Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M.A., Gladbach, A., van Eersel, J., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142 (2010), 387–397.
169. [169] Roberson, E.D., Halabisky, B., Yoo, J.W., Yao, J., Chin, J., Yan, F., et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31 (2011), 700–711.
170. [170] Hall, A.M., Throesch, B.T., Buckingham, S.C., Markwardt, S.J., Peng, Y., Wang, Q., et al. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease. J Neurosci 35 (2015), 6221–6230.
171. [171] DeVos, S.L., Goncharoff, D.K., Chen, G., Kebodeaux, C.S., Yamada, K., Stewart, F.R., et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci 33 (2013), 12887–12897.
172. [172] DeVos, S.L., Miller, T.M., Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 10 (2013), 486–497.
173. [173] Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E.V., Mazur, C., McAlonis, M.M., Pytel, K.A., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74 (2012), 1031–1044.
174. [174] Alonso, A.C., Zaidi, T., Grundke-Iqbal, I., Iqbal, K., Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A 91 (1994), 5562–5566.
175. [175] Binder, L.I., Frankfurter, A., Rebhun, L.I., The distribution of tau in the mammalian central nervous system. J Cell Biol 101 (1985), 1371–1378.
176. [176] Wood, J.G., Mirra, S.S., Pollock, N.J., Binder, L.I., Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci U S A 83 (1986), 4040–4043.
177. [177] Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 102 (2005), 227–231.
178. [178] Zhang, B., Carroll, J., Trojanowski, J.Q., Yao, Y., Iba, M., Potuzak, J.S., et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32 (2012), 3601–3611.
179. [179] Barten, D.M., Fanara, P., Andorfer, C., Hoque, N., Wong, P.Y., Husted, K.H., et al. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 32 (2012), 7137–7145.
180. [180] Hempen, B., Brion, J.P., Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol 55 (1996), 964–972.
181. [181] Cash, A.D., Aliev, G., Siedlak, S.L., Nunomura, A., Fujioka, H., Zhu, X., et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 162 (2003), 1623–1627.
182. [182] Brunden, K.R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J.S., Hogan, A.M., et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 30 (2010), 13861–13866.
183. [183] Fitzgerald, D.P., Emerson, D.L., Qian, Y., Anwar, T., Liewehr, D.J., Steinberg, S.M., et al. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 11 (2012), 1959–1967.
184. [184] Matsuoka, Y., Jouroukhin, Y., Gray, A.J., Ma, L., Hirata-Fukae, C., Li, H.F., et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325 (2008), 146–153.
185. [185] Matsuoka, Y., Gray, A.J., Hirata-Fukae, C., Minami, S.S., Waterhouse, E.G., Mattson, M.P., et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31 (2007), 165–170.
186. [186] Quraishe, S., Cowan, C.M., Mudher, A., NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry 18 (2013), 834–842.
187. [187] Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72 (1999), 1283–1293.
188. [188] Divinski, I., Mittelman, L., Gozes, I., A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279 (2004), 28531–28538.
189. [189] Gozes, I., Divinski, I., NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 4 (2007), 507–509.
190. [190] Gozes, I., Steingart, R.A., Spier, A.D., NAP mechanisms of neuroprotection. J Mol Neurosci 24 (2004), 67–72.
191. [191] Pedersen, J.T., Sigurdsson, E.M., Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21 (2015), 394–402.
192. [192] Congdon, E.E., Gu, J., Sait, H.B., Sigurdsson, E.M., Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 288 (2013), 35452–35465.
193. [193] Gu, J., Congdon, E.E., Sigurdsson, E.M., Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 288 (2013), 33081–33095.
194. [194] Guo, J.L., Lee, V.M., Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20 (2014), 130–138.
195. [195] Iba, M., Guo, J.L., McBride, J.D., Zhang, B., Trojanowski, J.Q., Lee, V.M., Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 33 (2013), 1024–1037.
196. [196] Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R.A., Frank, S., Hench, J., et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 110 (2013), 9535–9540.
197. [197] Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski, D., Frank, S., Probst, A., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11 (2009), 909–913.
198. [198] Boluda, S., Iba, M., Zhang, B., Raible, K.M., Lee, V.M., Trojanowski, J.Q., Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol 129 (2015), 221–237.
199. [199] Iba, M., McBride, J.D., Guo, J.L., Zhang, B., Trojanowski, J.Q., Lee, V.M., Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections. Acta Neuropathol 130 (2015), 349–362.
200. [200] Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82 (2014), 1271–1288.
201. [201] Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63 (2006), 1459–1467.
202. [202] Asuni, A.A., Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27 (2007), 9115–9129.
203. [203] Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., Rosenmann, H., Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224 (2010), 472–485.
204. [204] Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 248 (2013), 451–456.
205. [205] Schroeder, S.K., Joly-Amado, A., Gordon, M.N., Morgan, D., Tau-directed immunotherapy: a promising strategy for treating Alzheimer's disease and other tauopathies. J Neuroimmune Pharmacol 11 (2016), 9–25.
206. [206] Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18 (2015), 1584–1593.
207. [207] Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287 (2012), 3842–3849.
208. [208] Worley, S., After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say. P T 39 (2014), 365–374.
209. [209] Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108.
210. [210] Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., et al. Tau positron emission tomographic imaging in aging and early Alzheimer's disease. Ann Neurol 79 (2016), 110–119.
211. [211] Perry, D., Sperling, R., Katz, R., Berry, D., Dilts, D., Hanna, D., et al. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother 15 (2015), 327–333.